|
Press Releases |
|
|
|
Monday, December 9, 2024 |
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China |
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China more info >> |
|
Monday, December 2, 2024 |
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
Monday, October 21, 2024 |
|
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area |
China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. more info >> |
|
Tuesday, September 24, 2024 |
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
Friday, August 16, 2024 |
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
Monday, August 5, 2024 |
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
Tuesday, July 16, 2024 |
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
Tuesday, June 25, 2024 |
|
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China |
On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China. more info >> |
|
Tuesday, June 18, 2024 |
|
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China |
more info >> |
|
Tuesday, April 23, 2024 |
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China |
China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets ("Desidustat Tablets" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
BDO announces winners of the 6th BDO ESG Awards 2024
Dec 11, 2024 22:00 HKT/SGT
|
|
|
GMG's THERMAL-XR(R) Demonstrates Potential for Electronics Heat Sink Miniaturization and Efficiency
Dec 11, 2024 21:29 HKT/SGT
|
|
|
Volatus Aerospace Welcomes UK-Based Air Data Systems to its Ecosystem, Expanding Global Capabilities
Dec 11, 2024 20:45 HKT/SGT
|
|
|
Intelligent Joy Limited Signs MOU for Strategic Cooperation with First U.S. Capital Group (Revised)
Dec 11, 2024 18:30 HKT/SGT
|
|
|
Brawijaya University develops data system for climate change monitoring
Dec 11, 2024 15:40 HKT/SGT
|
|
|
Fujitsu concludes share transfer agreement concerning Fujitsu Communication Services Limited
Dec 11, 2024 16:36 JST
|
|
|
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 11, 2024 14:45 JST
|
|
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership
Dec 11, 2024 11:06 HKT/SGT
|
|
|
CELH Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Celsius Holdings, Inc. Investors of Securities Fraud Class Action Lawsuit Deadline
Dec 11, 2024 10:19 JST
|
|
|
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Wolfspeed, Inc.
Dec 11, 2024 10:15 JST
|
|
|
Combating customer harassment: Fujitsu, Toyo University and Kokoro Balance Research Institute launch field trial on AI-powered training program
Dec 11, 2024 10:11 JST
|
|
|
PACS Group, Inc. Investors: January 13, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Dec 11, 2024 10:10 JST
|
|
|
Acadia Healthcare Company, Inc. (ACHC) Investors: December 16, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Dec 11, 2024 10:05 JST
|
|
|
FxPro Group Announces the Launch of BankPro: A Private Digital Banking Solution
Dec 11, 2024 09:00 HKT/SGT
|
|
|
Photon Academy Unveils Solutions for Singapore's Growing Need for Evolving IB Tuition
Dec 11, 2024 08:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|